Brightgene Bio-Medical Technology Co. Ltd. has divulged new gastric inhibitory polypeptide receptor (GIPR), glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of neurodegeneration, bone, metabolic and cardiovascular disorders.